MONTPELLIER, France--(BUSINESS WIRE)--Reguilatory News:
MedinCell (Paris:MEDCL) (FR0004065605 - MEDCL), a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas announces today the filing of its 2019/2020 Universal Registration Document (URD) with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference R. 20-015.
The universal registration document notably includes:
- the annual financial report for the year ending on March 31, 2020;
- the management report;
- the CSR report; and
- the report on corporate governance.
An English version of the document will soon be available on the Company's website.
MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.